Inventor · disambiguated record
Robert Hofmeister
Also filed as: HOFMEISTER ROBERT
15 granted patents·17 pending applications·208 citations·filing 2001–2024
93Inventor score
Top patents by PatentIndex Score
32 records- 0197US11028142B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·6 cites·30 claims
- 0296US10442849B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Oct 15, 2019·21 cites·27 claims
- 0396US10208285B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·14 cites·20 claims
- 0495US11085021B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Aug 10, 2021·3 cites·27 claims
- 0595US8076459B2Multispecfic deimmunized CD3-bindersHOFMEISTER ROBERT·Filed 2004·Granted Dec 13, 2011·97 cites·31 claims
- 0694US9102736B2Multispecific deimmunized CD3-bindersHOFMEISTER ROBERT·Filed 2011·Granted Aug 11, 2015·37 cites·37 claims
- 0793US10358474B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·9 cites·30 claims
- 0892US11242376B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Feb 8, 2022·6 cites·19 claims
- 0988US10358473B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·4 cites·30 claims
- 1088US2024301026A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1184US11965012B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·27 claims
- 1284US11377638B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 5, 2022·1 cites·19 claims
- 1379US11851491B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Dec 26, 2023·1 cites·15 claims
- 1477US10808032B2Biological materials related to HER3ABLYNX NV·Filed 2018·Granted Oct 20, 2020·1 cites·20 claims
- 1577US2022298478A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1675US9932403B2Biological materials related to HER3KNUEHL CHRISTINE·Filed 2011·Granted Apr 3, 2018·3 cites·8 claims
- 1772US10000574B2Compositions comprising polypeptidesHOFMEISTER ROBERT·Filed 2004·Granted Jun 19, 2018·5 cites·15 claims
- 1871US2021206827A9Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1957US2023065936A1Compositions and methods for treating cancerTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2055US2023338421A1Compositions and methods for autoimmunity regulationTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2154US2021253666A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2254US2005176028A1Deimmunized binding molecules to CD3Filed 2004·Application pending·0 cites
- 2353US2021315933A1Compositions and methods for tcr reprogramming using target specific fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2453US2024252641A1Compositions and methods for tcr reprogramming using cd70 specific fusion proteinsTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2552US2024117002A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2652US2021361704A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2752US2023069322A1Compositions and methods for gamma delta tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2852US2022362295A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2949US2021079057A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3047US2021187022A1Engineered t cells for the treatment of cancerTCR2 THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3143US2009241202A1Domain-grafted antibodiesMICROMET AG·Filed 2006·Application pending·0 cites
- 3236US2004038339A1Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complexFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Hofmeister files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →